# QNTM catalysts: Quantum Biopharma Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/qntm/catalysts

> Quantum Biopharma Ltd. (QNTM) has no upcoming catalysts in this calendar. The latest recorded is the Quantum Biopharma Ltd. FDA approval, September 15, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Quantum Biopharma Ltd. |
| Ticker | QNTM (Nasdaq) |
| SEC CIK | 1771885 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/qntm |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 29, 2024 | [FSD-201 trial start](https://sec-api.dev/pdufa/fsd-201) | QNTM |  | completed | "On October 29, 2024, the Company announced that its subsidiary, Huge Biopharma, had initiated sentinel dosing in a Phase 1 clinical trial for Lucid-MS, a potential multiple sclerosis treatment, in Australia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771885/000165495424014085/fsd_ex992.htm)) |
| August 10, 2026 | [Quantum Biopharma Ltd. FDA approval](https://sec-api.dev/companies/qntm/catalysts) | QNTM |  | completed, approved | "TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma"), a transformative biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurological, metabolic, and alcohol misuse disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for Lucid-MS (Lucid-21-302), enabling Quantum BioPharma to immediately advance its patented, first-in-class multiple sclerosis program into Phase 2 clinical development." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771885/000117184326005370/exh_991.htm)) |
| September 15, 2026 | [Quantum Biopharma Ltd. FDA approval](https://sec-api.dev/companies/qntm/catalysts) | QNTM | progressive MS | completed, approved | "Recently Quantum BioPharma announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug application for Lucid-MS, to begin Phase 2 trials for the very first time to advance its patented, first-in-class multiple sclerosis ("MS") program in patients with progressive MS. This is currently an area of substantial unmet medical need within a global MS therapeutics market anticipated to reach approximately US$38.62 billion by 2030 (Grand View Research, 2026)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771885/000117184326006047/exh_991.htm)) |

## Drugs

- [FSD-201](https://sec-api.dev/pdufa/fsd-201): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/qntm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "QNTM catalysts: Quantum Biopharma Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/qntm/catalysts

```bibtex
@misc{secapidev_companies_qntm_catalysts_20261116,
  title        = {QNTM catalysts: Quantum Biopharma Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/qntm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_qntm_catalysts_20261116","title":"QNTM catalysts: Quantum Biopharma Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/qntm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
